1-(5-isoquinolinesulfonyl)-2-methylpiperazine and beraprost
1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with beraprost in 2 studies
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Fukumoto, Y; Shimokawa, H; Tawara, S | 1 |
Fukumoto, Y | 1 |
Reviews
1 review(s) available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and beraprost
Article | Year |
---|---|
[Role of the Rho-kinase pathway in pulmonary arterial hypertension].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bosentan; Drug Therapy, Combination; Epoprostenol; Humans; Hypertension, Pulmonary; Mice; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Rats; rho-Associated Kinases; Signal Transduction; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance | 2014 |
Other Studies
1 other study(ies) available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and beraprost
Article | Year |
---|---|
Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Drug Interactions; Drug Therapy, Combination; Epoprostenol; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Protein Kinase Inhibitors; Pulmonary Artery; Random Allocation; Rats; Rats, Sprague-Dawley; Vasodilator Agents | 2007 |